B Bilgin Global Mod Global Mod 2 Ocak 2024 #1 InvAscent looks to exit Aizant Drug at $350-400 mn valuation The investment firm has approached PE funds to buy a controlling stake in the drug development company
InvAscent looks to exit Aizant Drug at $350-400 mn valuation The investment firm has approached PE funds to buy a controlling stake in the drug development company
